Moreover, they showed the ability to tackle single or, even more, multiple factors, including ChEs, Aβ and tau proteins, as the most frequently affected targets, thus confirming a multitarget profile, that enables them as valuable candidates for AD therapy. This evidence concerns the gene MAPT and Alzheimer disease.